Valantin MA
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
-
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
-
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
-
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
-
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.